Tammy Mentzel, MPH, has been named Executive Director for Center Administration and Associate Director for Administration at the University of Cincinnati Cancer Center.

Andrew Waters, PhD, a basic scientist at the University of Cincinnati Cancer Center and assistant professor within the Division of Surgical Oncology and the Department of Cancer Biology at UC, runs a research lab focusing on the molecular consequences and resistance mechanisms to KRAS inhibitors.

The University of Cincinnati Cancer Center Clinical Trials Office recently opened a trial to study the efficacy of LN-145 on patients with advanced lung cancer. This treatment involves the infusion of patients’ own immune cells, tumor-infiltrating lymphocytes (TIL), to evaluate the efficacy of LN-145 as determined by objective response rates (ORR).

The Greater Cincinnati STEM Collaborative (GCSC) is a nonprofit that prepares students for future careers and educational pathways in science, technology, engineering and mathematics.

The K program (KL2 and CT2) Career Development program is focused on training the next generation of diverse, multidisciplinary clinical and translational scientists.

The Biomedical Research and Mentoring Program (RaMP) offers first-and second-year undergraduate University Honors students with training and experience in high-level biomedical research.

The University of Cincinnati Cancer Center Clinical Trials Office recently opened a trial to compare a lower-than-standard dosage of a widely used treatment in newly diagnosed acute myeloid leukemia (AML) patients. This clinical trial is designed to evaluate the efficacy this dosage and treatment schedule of Venetoclax plus Azacitidine may have for newly diagnosed AML patients.

By:

By:

By:

By: